Hiroshima Journal of Medical Sciences Volume 60 Issue 1
published_at 2011-03

Regression of a Primary Pulmonary Adenocarcinoma after Zoledronic Acid Monotherapy

Nagao Saeko
Hattori Noboru
Kanehara Masashi
Ishikawa Nobuhisa
fulltext
244 KB
HiroshimaJMedSci_60_7.pdf
Abstract
Bisphosphonates are widely used for the treatment of metastatic skeletal tumors and hypercalcemia resulting from malignant tumors. Zoledronic acid (ZOL), a third-generation bisphosphonate agent, was recently demonstrated to show synergistic antitumor activity of ZOL when combined with chemotherapy in lung cancer patients. However, whether ZOL exerts direct antitumor activity on lung cancer remains unclear. Here, we report an atypical case encountered while treating a 57-year-old woman with pulmonary adenocarcinoma and multiple metastases of the liver, left adrenal gland, and bone. The nonskeletal lesions, consisting of the primary lesion and hepatic metastasis, regressed after treatment with ZOL alone. We believe this case demonstrates a possible antitumor effect of ZOL against lung cancer.
Keywords
Lung cancer
Bone metastasis
Zoledronic acid
Anti-tumor effect
Rights
(c) Hiroshima University Medical Press.